灰指甲市场规模、份额和成长分析（按类型、治疗方法和地区）- 产业预测 2025-2032

2023 年全球灰指甲市场规模价值 53 亿美元，预计将从 2024 年的 55.4 亿美元成长到 2032 年的 78.8 亿美元，预测期间（2025-2032 年）的复合年增长率为 4.5%。

全球灰指甲市场专注于灰指甲的诊断和治疗，随着人们对指甲健康认识的不断提高以及老龄化、糖尿病和免疫力缺乏等疾病的日益流行，预计该市场将大幅增长。该市场包括外用和口服抗真菌药物、指甲油以及用于雷射治疗和指甲剥落的先进医疗设备等各种产品。主要企业包括製药公司、医疗设备製造商和医疗保健提供者，他们致力于研发、产品发布和策略联盟以扩大市场占有率。该市场的关键地区包括北美、欧洲和亚太地区，反映出对旨在改善全身健康的有效治疗和创新解决方案的强烈需求。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和资料资料
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

灰指甲市场规模（按类型和复合年增长率）（2025-2032）

• 市场概况
• 远端灰指甲
• 白色表浅性灰指甲
• 近端甲下甲灰指甲
• 其他的

灰指甲市场规模（按治疗方法和复合年增长率） (2025-2032)

• 市场概况
• 口服
• 局部的
• 其他的

灰指甲市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分析市场份额
  • 收益与前一年同期比较（2022-2024 年）

主要企业简介

• Bausch Health Companies Inc.（Canada）
• GSK plc（UK）
• Abbott（US）
• Pfizer Inc.（US）
• Bayer AG（Germany）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Cipla Inc.（India）
• Merck & Co., Inc.（US）
• Novartis AG（Switzerland）
• Sun Pharmaceutical Industries Ltd.（India）
• Sanofi（France）
• Johnson & Johnson（US）
• Eli Lilly and Company（US）
• Mylan NV（US）
• Galderma SA（Switzerland）
• Valeant Pharmaceuticals International, Inc.（Canada）
• Sandoz International GmbH（Germany）
• Lupin Limited（India）
• Dr. Reddy's Laboratories Ltd.（India）
• Aurobindo Pharma Limited（India）

结论和建议

Global Onychomycosis Market size was valued at USD 5.3 billion in 2023 and is poised to grow from USD 5.54 billion in 2024 to USD 7.88 billion by 2032, growing at a CAGR of 4.5% during the forecast period (2025-2032).

The global onychomycosis market, centered on the diagnosis and treatment of nail fungal infections, is poised for significant growth due to rising awareness of nail health and a growing prevalence of conditions such as aging, diabetes, and immune deficiencies. This market encompasses a variety of products including topical and oral antifungal medications, nail lacquers, and advanced medical devices for laser therapy and nail debridement. Key players include pharmaceutical firms, medical device manufacturers, and healthcare providers who are engaging in R&D, product launches, and strategic partnerships to enhance their market share. Major regions for this market include North America, Europe, and Asia Pacific, reflecting a strong demand for effective treatments and innovative solutions aimed at promoting overall well-being.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Onychomycosis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Onychomycosis Market Segmental Analysis

Global Onychomycosis Market is segmented by Type, Treatment and region. Based on Type, the market is segmented into Distal Subungual Onychomycosis, White Superficial Onychomycosis, Proximal Subungual Onychomycosis and others. Based on Treatment, the market is segmented into Oral, Topical and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Onychomycosis Market

The global onychomycosis market is significantly driven by the rising prevalence of various risk factors, including the growing rates of diabetes, an aging population, compromised immune systems, and instances of nail trauma. As these factors elevate the vulnerability to fungal infections, they result in an expanding demographic of patients seeking diagnosis and treatment for onychomycosis. Consequently, this surge in affected individuals underscores the increasing demand for effective therapeutic solutions, thereby propelling market growth. The correlation between these risk factors and the incidence of onychomycosis highlights the urgent need for improved awareness, prevention, and treatment options in the healthcare sector.

Restraints in the Global Onychomycosis Market

One of the significant constraints in the global onychomycosis market is the potential side effects and limitations linked to existing treatment modalities. Although oral antifungal drugs are recognized for their efficacy, they come with risks of systemic side effects, necessitating close monitoring of patients. Furthermore, topical treatments often struggle with effectiveness in addressing severe or deeply entrenched infections. These challenges can impede market expansion and complicate the delivery of safe and effective treatment alternatives for individuals affected by onychomycosis, ultimately affecting patient outcomes and clinician confidence in treatment strategies.

Market Trends of the Global Onychomycosis Market

The global onychomycosis market is witnessing a significant trend towards the development of innovative and convenient treatment solutions, driven by an increasing demand for therapies that prioritize efficacy, shorter treatment durations, and greater patient adherence. Market participants are actively investing in research and development to introduce novel options such as advanced topical formulations, specialized lacquers, and cutting-edge laser therapies. This shift not only enhances treatment effectiveness but also reflects a broader commitment within the industry to address the evolving needs of patients suffering from fungal nail infections, ultimately aiming to improve clinical outcomes and quality of life for affected individuals.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Onychomycosis Market Size by Type & CAGR (2025-2032)

• Market Overview
• Distal Subungual Onychomycosis
• White Superficial Onychomycosis
• Proximal Subungual Onychomycosis
• others

Global Onychomycosis Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Oral
• Topical
• others

Global Onychomycosis Market Size & CAGR (2025-2032)

• North America (Type, Treatment)
  • US
  • Canada
• Europe (Type, Treatment)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Treatment)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Treatment)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Treatment)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Bausch Health Companies Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Inc. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Galderma S.A. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Valeant Pharmaceuticals International, Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations